Detecting endometrial and ovarian cancer early using a genomic test
Official title: Phase III Diagnostic Trial for Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers
Run by McGill University · NCT04891029 · Data updated 2026-11-12
This study is testing a new genomic test to see if it can help find endometrial and ovarian cancers earlier in women who don't have any symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 75 Years |
| Sex | Women only |
| Enrollment | 5600 (estimated) |
| Sponsor | McGill University Academic / other |
| Locations | 2 sites (Montreal, Quebec and 1 other locations) |
| Status | Recruiting |
| Started | May 10, 2021 |
| Main results expected | November 2025 |
| Study ends | November 2028 |
| Registry record updated | June 17, 2025 |
| Trial ID | NCT04891029 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are asymptomatic women who are capable of providing informed consent.
✕Probably not a fit
Patients who have had a prior hysterectomy, are pregnant, nursing, undergoing fertility treatment, or have a recent history of uterine perforation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to improve the early detection of endometrial and ovarian cancers by utilizing a novel genomic assay called the DOvEEgene test. The research builds on previous findings that highlighted the limitations of current screening methods, such as transvaginal ultrasound and CA-125 tests, which often fail to identify cancers until they are at an advanced stage. By screening asymptomatic women, the study seeks to identify these cancers earlier in their development, potentially leading to better treatment outcomes. The study is being conducted at multiple locations in Montreal, Quebec, under the auspices of McGill University and its research partners.
Why it matters
Potential benefit: If successful, this approach could lead to earlier diagnosis and treatment of endometrial and ovarian cancers, improving survival rates.
How similar studies have gone: Previous studies have shown that early detection methods can improve outcomes, but this genomic approach is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Capacity to understand study and provide informed consent Exclusion Criteria: * Prior hysterectomy * Be pregnant * Be nursing * Be undergoing any fertility treatment * Have had recent history of uterine perforation
Where it's running
-
McGill University Health Centre, Royal Victoria Hospital
Montreal, Quebec, Canada Recruiting -
Queen Elizabeth Health Complex
Montreal, Quebec, Canada Recruiting
Study contacts
- Study coordinator: Lucy Gilbert, MD
- Email: gyne-oncologysec@mcgill.ca
- Phone: 514-934-1934
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart heartbeats: using PEG to separate macrotroponin from real troponin elevations
This study tests whether polyethylene glycol precipitation can distinguish macrotroponin from true troponin elevations in people with acute coronary syndrome and in healthy marathon runners.
-
Using artificial intelligence to improve cataract surgery outcomes for patients with high myopia
This study is testing a new artificial intelligence tool to see if it can help improve cataract surgery results for patients with severe nearsightedness by providing better lens calculations.
-
Screening for bronchopulmonary cancer in a structured network
This study is testing a new way to screen for lung cancer using special scans in a network of health centers to see if it helps catch the disease early.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.